Ajanta Pharma Ltd (AJANTPHARM)
🎯 Key Takeaways
- Ajanta Pharma is in a stable growth phase with strong profitability and improving margins, driven by consistent revenue expansion and disciplined cost management. Management is focused on sustainable scaling, ESG integration, and capital efficiency, supported by a healthy balance sheet and minimal debt.
- Revenue grew 14.4% QoQ to ₹1,626 in Q1FY27.
- ⚠️ Regulatory scrutiny in international markets, particularly the US and Europe, where pricing pressures and compliance requirements could impact export
- Market Cap
- ₹45,195
- P/E Ratio
- 39.8
- P/B Ratio
- 9.98
- ROE
- 25.1%
- ROCE
- 31.8%
- Debt/Equity
- 0.05
- Div Yield
- 0.77%
- Promoter
- 63.5%
📖 The Story
Ajanta Pharma is in a stable growth phase with strong profitability and improving margins, driven by consistent revenue expansion and disciplined cost management. Management is focused on sustainable scaling, ESG integration, and capital efficiency, supported by a healthy balance sheet and minimal debt. The company maintains a dominant promoter stake with stable institutional interest.
📰 What's Happening
In Q1FY27, Ajanta Pharma reported revenue of ₹1,626 crore, up from ₹1,422 crore in Q4FY26, with operating profit rising to ₹379 crore and OPM expanding to 23.3%. The company submitted its FY 2025-26 Sustainability Report (2026-09-30), highlighting a 47% reduction in Scope 1 emissions, 16.6 MW renewable energy capacity, and plans to achieve 50% renewable energy by FY 2027. Promoter Aayush Agrawal released 98,185 pledged shares (2026-09-28) to repay loans, reducing encumbrance but maintaining 11.29% ownership. Earlier, in August 2026 (2026-08-27), promoters released pledges on RBL Bank loans and created a new pledge with 360 One Prime Ltd, reflecting proactive debt management without altering overall promoter stake of 14.47% per trust.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,354 | 1,375 | 1,422 | 1,626 |
| Operating Profit | 285 | 339 | 288 | 379 |
| OPM % | 21.0% | 24.6% | 20.3% | 23.3% |
| Net Profit | 260 | 274 | 267 | 334 |
| EPS | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 |
Revenue has grown sequentially for four consecutive quarters, rising from ₹1,354 crore in Sep 2025 to ₹1,626 crore in Jun 2026, with operating margins improving from 20.3% to 23.3% despite macroeconomic pressures. Net profit and EPS have risen steadily, reaching ₹334 crore and ₹26.75 in Q1FY27, up from ₹260 crore and ₹20.83 in the prior year quarter. This growth is supported by margin expansion, indicating effective cost control and operational efficiency, which management attributes to pricing discipline and product mix optimization.
🔮 Management Outlook & What's Next
In its FY 2025-26 Sustainability Report (2026-09-30), management outlined ambitious ESG targets, including 50% renewable energy by FY 2027, 100% by FY 2032, 20% reduction in Scope 1 and 2 emissions by March 2027, and 1.5 lakh KL water conservation potential by FY 2027. It also aims for 15% women board representation by 2030. While these are long-term goals, they reflect a strategic shift toward sustainable operations and stakeholder-centric governance, with external assurance from TÜV India adding credibility to disclosures.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 |
| Reserves | 3,765 | 3,652 | 4,502 | 4,290 |
| Borrowings | 47 | 33 | 212 | 246 |
| Total Liabilities | 5,015 | 4,791 | 6,155 | 5,672 |
| Fixed Assets | 1,716 | 1,438 | 1,867 | 1,832 |
| Investments | 464 | 702 | 588 | 874 |
| Total Assets | 5,015 | 4,791 | 6,155 | 5,672 |
The balance sheet shows a strong equity base of ₹25 crore with reserves growing to ₹4,502 crore as of Mar 2026, up from ₹3,765 crore in FY 2024-25, indicating robust retained earnings. Borrowings remain low and stable at ₹212 crore, down from ₹47 crore a year ago, reflecting conservative capital structure and deleveraging trend. Total assets have grown to ₹6,155 crore, driven by operational expansion, while equity and reserves growth outpaces asset growth, suggesting capital efficiency and financial resilience.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +529 |
| Investing | -429 |
| Financing | -168 |
| Net Cash Flow | -68 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 66.3% | 66.3% | 66.3% | 63.5% |
| FII | 8.5% | 8.0% | 8.3% | 7.7% |
| DII | 17.9% | 18.6% | 18.4% | 21.8% |
| Public | 6.5% | 6.4% | 6.3% | 6.3% |
| # Shareholders | 67,785 | 65,409 | 67,955 | 65,296 |
Promoter holding has declined slightly from 66.25% in Q4FY26 to 63.48% in Q1FY27, but remains dominant. Institutional investors (FII) increased holdings from 7.98% in Q3FY26 to 8.26% in Q4FY26, while DII rose from 17.9% to 18.36% in the same period, indicating growing institutional confidence. The number of shareholders has also increased to 65,296 in Q1FY27 from 65,409 in Q3FY26, suggesting broadening retail interest and improving market participation.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Regulatory scrutiny in international markets, particularly the US and Europe, where pricing pressures and compliance requirements could impact export revenues. 2. Rising input costs and raw material inflation, which may pressure margins if not fully passed on to customers. 3. Concentration in regulated markets exposing the company to geopolitical and currency risks. 4. Execution risk around ESG targets, which require significant capital expenditure and operational changes without guaranteed ROI.
📋 Recent Filings
- 🔴 Insider Trading2026-10-01Ajanta Pharma disclosed that CTL Trusteeship Limited pledged 26,21,067 shares (2.10% of total) and 92,53,718 shares (7.41% of total) as security for d…
- 🟡 sustainability report2026-09-30Ajanta Pharma submitted its FY 2025-26 Sustainability Report, detailing ESG performance across environmental, social and governance metrics. The repor…
- 🔴 Insider Trading2026-09-28Promoter Aayush Agrawal released pledges on 98,185 shares of Ajanta Pharma Ltd on 28 September 2026 to repay loans, reducing encumbered holdings. The …
- Announcement2026-09-25Ajanta Pharma announced that its insider trading window will close on 1 October 2026 and remain shut for 48 hours after the Q2 and H1 results ending 3…
- Announcement2026-08-31Ajanta Pharma announced its schedule for upcoming investor meetings with Jefferies India Forum on September 16, 2026, and PL Capital Mid & Small Cap C…
- 🔴 Insider Trading2026-08-27Ajanta Pharma Ltd disclosed that promoter group entities including Yogesh Agrawal Trust, Rajesh Agrawal Trust, and Ravi Agrawal Trust released pledges…
- Announcement2026-08-05Ajanta Pharma announced its schedule for analyst and institutional investor meetings in August 2026, including one-on-one sessions at the Nuvama India…
- Announcement2026-08-03Ajanta Pharma announced that a written transcript of its Q1 FY26 earnings call held on July 30, 2026, is now available on its website, providing inves…
- 🟡 Board Meeting2026-07-30Ajanta Pharma announced its Q1 FY2027 results on 30 July 2026, reporting 25% revenue growth to Rs 1,626 crore and 31% PAT growth to Rs 334 crore. The …
- Announcement2026-07-30Ajanta Pharma announced that an audio recording of its earnings call held on 30 July 2026 is now available on its website, with a transcript to follow…
🧠 Analyst's Read
Ajanta Pharma demonstrates consistent financial momentum and strategic foresight in sustainability and governance, but its long-term trajectory hinges on execution in regulated geographies and margin resilience amid cost volatility. Investors should monitor USFDA inspection outcomes, pricing trends in key markets, and progress on ESG milestones for early signals of operational and strategic execution.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AJANTPHARM files new disclosures
Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AJANTPHARM — FreeFree account · 2 AI queries/day